Bausch andamp; Lomb Begins Distribution Of VYZULTA(TM) (latanoprostene bunod ophthalmic solution), 0.024% To U.S. Wholesalers

LAVAL, Quebec, Dec. 18, 2017 -- (Healthcare Sales & Marketing Network) -- Valeant Pharmaceuticals International, Inc.'s (NYSE: VRX and TSX: VRX) ("Valeant") wholly owned subsidiary, Bausch & Lomb, a leading global eye health company, today ... Biopharmaceuticals, Ophthalmology, Product Launch Valeant Pharmaceuticals, Bausch & Lomb, VYZULTA, latanoprostene, glaucoma
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news